KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Average (2016 - 2026)

Fulgent Genetics' Equity Average history spans 11 years, with the latest figure at $1.1 billion for Q1 2026.

  • On a quarterly basis, Equity Average fell 4.25% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 4.25% decrease, with the full-year FY2025 number at $1.1 billion, down 0.94% from a year prior.
  • Equity Average hit $1.1 billion in Q1 2026 for Fulgent Genetics, down from $1.1 billion in the prior quarter.
  • Over the last five years, Equity Average for FLGT hit a ceiling of $1.3 billion in Q2 2022 and a floor of $1.1 billion in Q1 2026.
  • Historically, Equity Average has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2024.
  • Biggest five-year swings in Equity Average: surged 80.81% in 2022 and later dropped 10.98% in 2024.
  • Tracing FLGT's Equity Average over 5 years: stood at $1.3 billion in 2022, then dropped by 6.12% to $1.2 billion in 2023, then dropped by 5.47% to $1.1 billion in 2024, then decreased by 1.38% to $1.1 billion in 2025, then fell by 3.43% to $1.1 billion in 2026.
  • Business Quant data shows Equity Average for FLGT at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.